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Assessment of myocardial viability and ischemia
continues to be an important issue in patients with
coronary artery disease and left ventricular dysfunc-
tion [1–10]. In particular in patients following a
myocardial infarction and in the evaluation of patients
eligible forinterventional procedures suchas coronary
artery bypass grafting (CABG), accurate assessment
of myocardial viability remains pivotal [11–14]. To
assess myocardial viability, different diagnostic meth-
ods are currently performed, such as FDG/PET, MRI,
SPECT, and echocardiography [15–28]. In the clinical
arena, detection of myocardial viability is predomi-
nantly based on the use of nuclear techniques, which
showpreservedtraceruptakeandmetabolisminviable
myocardium. FDG/PET is considered the reference
standardduetoitsabilitytodifferentiatedysfunctional
but viable myocardium from scar formation and
normal myocardium [29–38]. In patients with ische-
mic cardiomyopathy, CABG offers an important
therapeutic option but this operative procedure is still
associated with a high perioperative mortality.
Although previous studies suggest a beneﬁt from
revascularization for patients with deﬁned viability by
a non-invasive technique [39–44], the role of viability
assessment to determine suitability for revasculariza-
tion in patients with ischemic cardiomyopathy has not
yet been deﬁned.
In the current issue of the International Journal of
Cardiovascular Imaging, Boehm et al. [45] evaluated
the hypothesis that the use of PET imaging in the
decision-making process for CABG will improve
postoperative patient survival. The authors studied
476 patients with ischemic cardiomyopathy (left ven-
tricular ejection fraction\35%) who were considered
candidates for CABG. In a Standard Care Group, 298
patients underwent CABG. In a second PET-guided
management group (n-178), 152 patients underwent
PET-CABG; 26 patients were excluded from CABG
because of lack of viability. The survival rate after 1, 5
and 9.3 years was 92.0, 73.3 and 54.2% in the PET-
CABGgroupand88.9,62.2and35.5%intheStandard
Care Group, respectively (P = 0.005). There was a
statisticallysigniﬁcantinﬂuenceonlong-termsurvival
usingFDG-PETdata,leftventricularfunction,andage
over 70 years. Consequently, preoperative assessment
of myocardial viability trough FDG-PET imaging
identiﬁed patients who will beneﬁt most from CABG.
The crucial ﬁnding of the present study was the
signiﬁcant reduction of the 30-day mortality in the
PET-CABG group with 1.3 vs. 10.3% in the Standard
Care group. The observed early mortality rate of
1.3% in the PET-CABG group is lower than observed
in the STICH trial (Surgical Treatment for Ischemic
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5% [46]. The early survival beneﬁt of the PET-
CABG group persisted in the long-term as reﬂected
by the superior survival of the PET-CABG over a
10 year follow-up. Another important message of the
present study was that he criterion of scar extent
alone was not sufﬁcient for the selection process.
Four patients in the PET-CABG group showed a scar
tissue area C40%. However, in these patients the
other main viability criteria and the angiographic
report supported the decision that these patients were
adequate candidates for CABG.
TheconceptofapreoperativePET-basedselectionof
patientswho beneﬁt mostly fromCABG was examined
by Haas et al. [47] who found a signiﬁcant reduction in
perioperativemortalityinpatientwithdeﬁnedviability.
In the PARR-2 study (positron emission tomography
andrecoveryfollowingrevascularization),patientswith
ischemiccardiomyopathywererandomizedtomanage-
ment guided by FDG-PET (n = 218) or standard care
(n = 212)[48].Inasubgroupofpatientswhoadheredto
PET recommendations regarding revascularization,
signiﬁcant survival beneﬁts were observed. These
ﬁndings are supported by the present study of Boehm
etal.[45]inwhicheverypatientwithsufﬁcientviability
in the PET-assisted group underwent CABG and
showed signiﬁcantly improved mortality rates after
revascularization.
The current study did not compare FDG-PET with
other imaging modalities for detection of viable myo-
cardiumsuchasgatedSPECTimaging,MRIorlowdose
dobutamine echocardiography, which may have pro-
vided additional important information in the decision
process for CABG. To that purpose, Siebelink et al. [49]
sought to prospectively compare nitrogen-13 (13 N)-
ammonia/18FDG-PET guided management with stress/
rest 99mTc-sestamibi SPECT-guided management in
103 patients considered for revascularization with left
ventricular wall motion abnormalities and suspicion of
jeopardized myocardium. In terms of cardiac event-free
survival, no differences between PET and SPECT were
observed (11 vs. 13 cardiac events for PET and SPECT,
respectively). No differences in patient management or
cardiac event-free survival were demonstrated between
management based on 13 N-ammonia/18FDG PET and
that based on stress/rest 99mTc-sestamibi SPECT
imaging. Both techniques may be used for viability-
guided management of patients considered for revascu-
larization with suspicion of jeopardized myocardium.
To summarize, the study by Boehm et al. [45]
reemphasizes the need for accurate preoperative
viability imaging in patients with ischemic cardio-
myopathy. Viability guided assessment may result in
a signiﬁcant reduction of peri-operative mortality
rates after CABG. However, the question of viability
assessment to determine suitability for revasculariza-
tion is still not fully resolved and an optimal
diagnostic protocol in patients with ischemic cardio-
myopathy has to be deﬁned. Consequently, larger
studies are necessary to further evaluate the impact of
preoperative viability assessment in this high-risk
group of patients.
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